Status:
TERMINATED
Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Melanoma
Eligibility:
All Genders
Brief Summary
RATIONALE: Studying samples of blood from patients with cancer, hepatitis C, or Crohn disease in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers rela...
Detailed Description
OBJECTIVES: * To determine how a variety of immune-modulating therapies (i.e., interferon alfa \[IFN-α\] in patients with untreated acute or chronic hepatitis C, anti-tumor necrosis factor in patient...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of 1 of the following:
- Acute or chronic hepatitis C
- Receiving pegylated interferon alfa and ribavirin
- Metastatic melanoma
- Receiving ticilimumab
- Crohn disease
- Received prior infliximab
Exclusion
- Not specified
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Key Trial Info
Start Date :
October 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT00897312
Start Date
October 1 2006
End Date
August 1 2008
Last Update
April 25 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.